MS
NTLA icon

Mizuho Securities’s Intellia Therapeutics NTLA Stock Holding History

Mizuho Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,900
Closed -$64K – 157
2019
Q2 		$64K Buy
+3,900
New +$61.3K 0.08% 97

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mizuho Securities's NTLA Position: Q3 2019 in Review

Mizuho Securities sold out of Intellia Therapeutics (NTLA) in Q3 2019, closing a stake of 3,900 shares — an estimated $64K sold.

Mizuho Securities first reported a position in NTLA in Q2 2019 and held it in 1 quarter. The position peaked at $64K in Q2 2019. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

  • Mizuho Securities reported no remaining Intellia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Mizuho Securities sold 3,900 Intellia Therapeutics shares in Q3 2019, an estimated $64K.
  • Mizuho Securities first reported a position in Intellia Therapeutics in Q2 2019 and held it in 1 quarter.
  • Mizuho Securities's Intellia Therapeutics position peaked at $64K in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on Mizuho Securities's 13F filing for Q3 2019, filed 14 Nov 2019.